Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis

Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy

(2019) Pamela C. Rosato et al.   Nature Communications

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Live or Let Die: T Cell Survival in Cancer Immunotherapy

(2019) Janne Ruotsalainen et al.   IMMUNITY

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

(2019) Elisabeth Perez-Ruiz et al.   NATURE

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

(2019) Omar Khan et al.   NATURE

Life-long control of cytomegalovirus (CMV) by T resident memory cells in the adipose tissue results in inflammation and hyperglycemia

(2019) Nico A. Contreras et al.   PLoS Pathogens

Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss

(2019) Graciela Andrei et al.   ANTIVIRAL RESEARCH

Management of immune related adverse events induced by immune checkpoint inhibition

(2019) Andreas Teufel et al.   CANCER LETTERS

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8 + T Cells by Persistent Viruses and Vaccines

(2018) Claire Louse Gordon et al.   Cell Reports

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade

(2018) Robert W. Wilkinson et al.   Frontiers in Immunology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

(2018) Arabella Young et al.   Cancer Immunology Research

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

(2018) Niklas Verloh et al.   EJNMMI Research

Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis

(2017) Cindy Franklin et al.   EUROPEAN JOURNAL OF CANCER

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

(2017) Takeo Fujii et al.   INVESTIGATIONAL NEW DRUGS

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

(2017) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein

(2017) B. A. Krishna et al.   Nature Communications

Tissue-specific control of latent CMV reactivation by regulatory T cells

(2017) Maha Almanan et al.   PLoS Pathogens

Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study

(2016) M. Peghin et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

(2016) David Y. Oh et al.   CANCER RESEARCH

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

(2016) Maria Del Castillo et al.   CLINICAL INFECTIOUS DISEASES

Compartmentalized dynamics of cytomegalovirus replication in treated congenital infection

(2016) S.E. Luck et al.   JOURNAL OF CLINICAL VIROLOGY

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

When polymerase chain reaction does not help: cytomegalovirus pneumonitis associated with very low or undetectable viral load in both blood and bronchoalveolar lavage samples after lung transplantation

(2016) J. Coussement et al.   Transplant Infectious Disease

An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET

(2016) Frank Hofheinz et al.   EJNMMI Research

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytomegalovirus disease in immunocompetent adults

(2015) Daniel Lancini et al.   MEDICAL JOURNAL OF AUSTRALIA

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Virologic and Immunologic Evidence Supporting an Association between HHV-6 and Hashimoto's Thyroiditis

(2012) Elisabetta Caselli et al.   PLoS Pathogens